HIGHOutside partySupplier
CordenPharma
“10-K Item 1: 'Corden Pharma Colorado, Inc. and its affiliates, or CordenPharma, covering both the active pharmaceutical ingredient, or API, and final finished product supply for VK2735'”
VKTX · Concentration risk · 10-K extracted
Viking Therapeutics (VKTX) concentration risks
Updated
The most significant concentration Viking Therapeutics discloses is CordenPharma, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Viking Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH2
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partyCounterparty
Ligand Pharmaceuticals
“10-K Item 1A: 'Our business is substantially dependent upon technology licensed from Ligand'”
MEDIUMBuilt-in & outside partyPipeline
VK2735 subcutaneous
“10-K Item 1A: 'VK2735 subcutaneous, which is in Phase 3 development'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is characteristic of a clinical-stage biopharmaceutical firm: a small number of high-share dependencies with no revenue base yet to diversify against. The most significant supply-side exposure is the manufacturing relationship with CordenPharma, which covers both the active pharmaceutical ingredient and final finished product supply for VK2735 — a high-share dependency. Because manufacturing for a single pipeline asset is concentrated in one partner, any disruption to that relationship would directly affect the company's ability to supply clinical or commercial product. Equally prominent is the technology licensing dependency on Ligand Pharmaceuticals, from which the business is described as substantially dependent. This is a high-share counterparty exposure: the underlying intellectual property foundation of the enterprise rests on a licensed relationship, and any material adverse change to that license would affect the viability of the portfolio. Layered on both is the binary nature of the lead asset: VK2735 subcutaneous, which is in Phase 3 development, represents a medium-share pipeline concentration with mixed character — it is both a structural focus of the company's strategy and an idiosyncratic binary event tied to regulatory outcomes. On balance, the concentration profile is narrow and interlocking: supply chain, licensing, and pipeline risk all converge on a single compound and a single technology platform, making each element mutually reinforcing rather than independent.
For the engine’s reasoning on VKTX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| VKTX● | Viking Therapeutics, Inc. | 2 | 1 | 0 | 3 |
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.